




RealRate

PHARMACEUTICAL 2022

Heron Therapeutics INC DE
Rank 395 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Heron Therapeutics INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Heron Therapeutics INC DE compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 1.3% points. The greatest weakness of Heron Therapeutics INC DE is the variable Stockholders Equity, reducing the Economic Capital Ratio by 145% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 135% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	254,423
Cost of Goods Sold	46,021
Intangible Assets	0
Liabilities, Current	71,058
Liabilities, Non-Current	7,996
Other Assets	27,549
Other Compr. Net Income	-263
Other Expenses	87,179
Other Liabilities	149,082
Other Net Income	-2,855
Other Revenues	86,346
Property and Equipment	23,734
Research and Development	130,821
Selling, General and Administrative Expense	40,153

Output Variable	Value in 1000 USD
Assets	305,706
Liabilities	228,136
Expenses	304,174
Revenues	86,346
Stockholders Equity	77,570
Net Income	-220,683
Comprehensive Net Income	-220,814
BaseVar	463,740
ECR before Limited Liability	-19%
Economic Capital Ratio	141%